



September 16, 2016

Sage Therapeutics to Present at the Neurocritical Care Society 14th Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced upcoming poster presentations at the Neurocritical Care Society 14th Annual Meeting, taking place from September 15-18 in National Harbor, Md.

Below is the schedule for the poster presentations:

Date: Friday, September 16, 2016
Poster Presentation Time: 5:30 p.m. - 6:30 p.m. EDT
Location: Gaylord National Resort & Convention Center, Prince George Exhibit Hall A
Poster Number: 10

Title: Preclinical Pharmacology and Pharmacodynamic Interactions of SAGE-547: Relevance to Super-Refractory Status Epilepticus

Date: Friday, September 16, 2016
Poster Presentation Time: 5:30 p.m. - 6:30 p.m. EDT
Location: Gaylord National Resort & Convention Center, Prince George Exhibit Hall A
Poster Number: 168

Title: Pharmacokinetics of SAGE-547 in Patients with Super-Refractory Status Epilepticus

Date: Friday, September 16, 2016
Poster Presentation Time: 5:30 p.m. - 6:30 p.m. EDT
Location: Gaylord National Resort & Convention Center, Prince George Exhibit Hall A
Poster Number: 172

Title: SAGE-547 (allopregnanolone injection) for the Treatment of Super-Refractory Status Epilepticus: Response and Relationship to Underlying Patient Characteristics

Date: Friday, September 16, 2016
Poster Presentation Time: 5:30 p.m. - 6:30 p.m. EDT
Location: Gaylord National Resort & Convention Center, Prince George Exhibit Hall A
Poster Number: 174

Title: Phase 1/2 Open-Label Data Suggest that Heterogeneity of Presentation and High Burden of Comorbid Illness Do Not Impact the Activity of SAGE-547 in Patients with Super-Refractory Status Epilepticus

Date: Saturday, September 17, 2016

Poster Presentation 5:30 p.m. - 6:30 p.m. EDT

Time:

Location: Gaylord National Resort & Convention Center, Prince George Exhibit Hall A

Poster Number: 165

Title: Hemodynamic Properties of SAGE-547 in Patients with Super-Refractory Status Epilepticus: Results from a Phase 1/2 Clinical Trial

In addition, Sage will host a lunch symposium featuring key opinion leaders. Details are as follows:

Date: Saturday, September 17, 2016

Time: 12:00 p.m. - 1:00 p.m. EDT

Location: Gaylord National Resort & Convention Center, Maryland Ballroom C

Title: Diagnosis and Management of Super-Refractory Status Epilepticus

About Sage Therapeutics

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder, and is being developed for postpartum depression. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, with a focus on acute and chronic CNS disorders. For more information, please visit www.sagerx.com.

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20160916005142/en/>

Investors:

Sage Therapeutics

Paul Cox, 617-299-8377

paul.cox@sagerx.com

or

Media:

Suda Communications LLC

Maureen L. Suda, 585-387-9248

maureen.suda@sagerx.com

Source: Sage Therapeutics

News Provided by Acquire Media